RT Journal Article
SR Electronic
T1 A simple protein-based SARS-CoV-2 surrogate neutralization assay
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.07.10.197913
DO 10.1101/2020.07.10.197913
A1 Kento T. Abe
A1 Zhijie Li
A1 Reuben Samson
A1 Payman Samavarchi-Tehrani
A1 Emelissa J. Valcourt
A1 Heidi Wood
A1 Patrick Budylowski
A1 Alan Dupuis
A1 Roxie C. Girardin
A1 Bhavisha Rathod
A1 Karen Colwill
A1 Allison J McGeer
A1 Samira Mubareka
A1 Jennifer L. Gommerman
A1 Yves Durocher
A1 Mario Ostrowski
A1 Kathleen A. McDonough
A1 Michael A. Drebot
A1 Steven J. Drews
A1 James M. Rini
A1 Anne-Claude Gingras
YR 2020
UL http://biorxiv.org/content/early/2020/07/11/2020.07.10.197913.abstract
AB With the COVID-19 pandemic surpassing 12M confirmed cases and 550K deaths worldwide, defining the key components of the immune response to SARS-CoV-2 infection is critical. Of particular importance is the identification of immune correlates of infection that would support public health decision-making on treatment approaches, vaccination strategies, and convalescent plasma therapy. While ELISA-based assays to detect and quantitate antibodies to SARS-CoV-2 in patient samples have been developed, the detection of neutralizing antibodies typically requires more demanding cell-based viral assays. Here, we present and validate a safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) with its receptor, angiotensin converting-enzyme 2 (ACE2). This test is performed on the same platform and in parallel with an enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against the RBD and serves as a surrogate neutralization assay.Competing Interest StatementSteven J Drews has acted as a content expert for respiratory viruses for Johnson & Johnson (Janssen). Work in the Gingras lab was partially funded by a contribution from QuestCap through the Sinai Health Foundation. The other authors declare no relevant conflicts of interest.